Biomarker Technologies Market Global Analysis and Forecast Report 2019 to 2026 | Industry Key Players - Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, LI-COR, Merck KGAA, PERKINELMER, QIAGEN

Premium Market Insights has Published New Research Report on – “Biomarker Technologies Market – Global Industry Analysis, Size, Overview, Trends, Growth and Forecast 2019 to 2026.”

The report on “Biomarker Technologies Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims.

The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.

Get PDF sample copy:
https://www.premiummarketinsights.com/sample/AMR00015585

Companies Covered in this Report are:
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche AG
Illumina, Inc.
LI-COR, Inc.
Merck KGAA
PERKINELMER INC.
QIAGEN
Shimadzu Corporation
Thermo Fisher Scientific, Inc.

Biomarker is a biological marker, which indicates a substance or a physical event. These indicated substances or events can be measured and the measurements can be further used for the detection of diseases, a physiological change, response to a treatment and a psychological condition. Biomarker technologies are different techniques, which are employed for testing various diseases. These technologies employ the use of different products to measure a biomarker. Reagents and assays are used in various biomarker technologies such as next generation sequencing, polymerase chain reaction, and others. These biomarker technologies are used in various fields of science such as drug discovery, diagnostics, and personalized medicine. Majorly biomarkers are used to detect diseases such as cancer, infectious diseases, autoimmune diseases, neurological disorders, and others.

Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.

The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

To Purchase This report details at: https://www.premiummarketinsights.com/buy/AMR00015585

KEY MARKET SEGMENTS
By Product
– Consumables
o Assay
o Reagent
– Instruments

By Technology
– Polymerase Chain Reaction (PCR)
– Next Generation Sequencing (NGS)
– Immunoassay
– Others

By Application
– Drug Discovery
– Diagnostics
– Personalized Medicine

By Indication
– Cancer
– Infectious Diseases
– Autoimmune Disorders
– Cardiovascular Disorders
– Others

By Region
– North America
o U.S.
o Canada
o Mexico
– Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
– Asia-Pacific
o India
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
– LAMEA
o Brazil
o South Africa
o Rest of LAMEA

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
– Eurofins Scientific
– Enzo Biochem, Inc.
– EKF Diagnostics Holdings plc
– Myriad Genetics, Inc. (Myriad RBM.).
– Becton, Dickinson and Company

Contact Us:
Name: Sameer Joshi
Organization: Premium Market Insights
Email: sales@premiummarketinsights.com
Phone: +1-646-491-9876

About Premium Market Insights:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

This release was published on openPR.